135,136 It is considered a significant breakthrough in diabetes treatment and is also being studied for the treatment of obesity due to its significant weight loss effects
[4] [6] The mechanism of action involves several complementary pathways
Randomized controlled trials are underway, regulatory decisions lie ahead, and real-world data will continue to accumulate
Advancements In GLP-1 Agonist Therapies For Diabetes And Weight Management GLP-1 agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists mimic naturally occurring incretin hormones to slow gastric emptying, increase the feeling of fullness, promote insulin secretion, and inhibit the inappropriate release of glucagon
Obesity occurs in conditions with excess secretion of glucocorticoids such as Cushing syndrome
Pregnancy and breastfeeding : GLP-1 receptor agonists are not recommended during pregnancy